Abstract
This article refers to 'The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics', by J.J.V. McMurray et al., published in this issue on pages 1402-1411.
Original language | English |
---|---|
Pages (from-to) | 1412-1414 |
Number of pages | 3 |
Journal | European Journal of Heart Failure |
Volume | 21 |
Issue number | 11 |
DOIs | |
Publication status | Published - Nov-2019 |